This retrospective analysis evaluated 51 children (0.7-17 years; median eight) with high-risk or advanced hematological malignancies, including 18 (35%) patients undergoing second/third hematopoietic SCT (allo-HSCT), not eligible for standard myeloablative regimens and transplanted from matched sibling (MSD) (n ¼ 24) or matched unrelated (MUD) (n ¼ 27) donors. Preparative regimens were based on treosulfan (TREO) i.v., a structural analog of BU, given at total dose of 30 g/m 2 (n ¼ 21) or 36-42 g/ m 2 (n ¼ 30) in combination with, fludarabine, cyclophosphamide, melphalan and/or VP-16 according to diagnosis, and risk factors. Deaths due to early regimenrelated toxicity (RRT) did not occur. Nonrelapse mortality was 8% at 1 year and 16% after 4 years. Myeloid engraftment was achieved in 94%, complete donor chimerism in 90% of patients. A 4-year incidence of relapse was 24%, and was significantly lower after MUD-HSCT (8%) than after MSD-HSCT (39%), but similar in children undergoing first (28%) or second/third HSCT (17%). A 4-year disease-free survival was 61%, but it was significantly better in myeloid (73%), than in lymphoid malignancies (41%). Thus, children with high-risk and advanced hematological malignancies and high-risk of life-threatening RRT can be transplanted effectively and safely using TREO-based regimens. Particularly favorable results were achieved in myeloid malignancies and in children undergoing second HSCT.
Introduction
The risk of severe early and late toxicity related to standard, myeloablative preparative regimens (standardprep-reg) for allogeneic hematopoietic SCT (allo-HSCT is especially high in the youngest children and in those who demonstrate pretransplant organ impairment. [1] [2] [3] Admittedly, reduced intensity conditioning (RIC) regimens diminish the risk of severe regimen-related toxicity (RRT), but they are accompanied by an increased rate of graft failure, GVHD, and late infections as well as by a higher relapse incidence. 4, 5 Therefore, there is still a need for conditioning regimens with myeloablative, immunosuppressive and anti-leukemic efficacy, that are at least comparable with that of BU-and fractionated TBI-based regimens, but with lower incidence of severe-early-and late RRT.
The results achieved by Casper et al. 6 in a pilot study, and then confirmed in a larger group of adult patients, 7 demonstrated that these objectives for an improved preparative regimen were obtained by treosulfan-based regimens, including nonhematopoietic organ toxicity comparable with, or even less prevalent than, that produced by RIC. Treosulfan (TREO) (L-threitol-1,4-bis-methanesulfonate) 8 is a structural analog of BU nonenzymatically activated to alkylating monoand diepoxides. It demonstrates cytotoxic/antiproliferative activity against a wide range of hematological malignancies and solid tumors, including important childhood malignancies. [9] [10] [11] [12] [13] In addition, TREO reveals an excellent hematopoietic stem cell toxicity and immunosuppressive effects, which are even superior to those of BU. 14, 15 As shown in adults, an additional advantage of TREO lies also in its predictable linear pharmacokinetics over a broad i.v. dosage range of 8-56 g/m 2 , which is in opposition to BU, and presumably follows the fact that TREO does not undergo hepatic metabolism. 16 Recently the preliminary study confirmed the linear pharmacokinetics of high-dose TREO after its single i.v. infusion of 10, 12 and 14 g/m 2 , as used in children. 17 However, variability of area under the concentration curve and maximum plasma concentration (C max ) observed in seven children studied demonstrated the need for further pharmacokinetic studies in pediatric patients. Conventionally dosed TREO is limited only by hematotoxicity, 18 whereas the dose-limiting toxicity of fractionated high-dose TREO is mucosal toxicity. 16 Thus, the TREO-based preparative regimens appeares to be especially suitable for patients with preexisting comorbidities, including liver comorbidities.
With reference to these results, in 2000 Wachowiak et al. 19 implemented the first TREO-based preparative regimen (TREO-prep-reg) for children with nonmalignant disorders and hematological malignancies, who were not eligible for standard preparative regimens because of high risk of RRT pretransplant.
To evaluate the European experience on the use of TREOprep-reg in children and adolescents, a retrospective study within the EBMT Pediatric Disease Working Group was performed.
Patients and methods

Patient characteristics
The retrospective study evaluated 51 children and adolescents with hematological malignancies who had undergone allo-HSCT between October 12, 2000 and December 31, 2005 in six pediatric transplant centers from four European countries (Austria, Germany, Poland and United Kingdom) and fulfilled the following eligibility criteria: (1) received TREO-based preparative regimen and (2) demonstrated pretransplant factors of increased risk of conventional preparative regimen toxicity and/or (3) received a second or subsequent HSCT and/or (4) demonstrated malabsorption syndrome and/or (5) failed to give consent to an oral BU-based regimen, (6) had matched sibling donor (MSD) or matched unrelated donor (9-10/10 HLA allele match) (MUD), and (7) were p18 years old at time of HSCT. The detailed patient characteristics are shown in Table 1 . As pretransplant factors of increased risk of standard regimen-related toxicity the each second or subsequent HSCT, and all life-threatening infectious complications and/or non-hematopoietic organ toxic injury (WHO grade IV) observed during the induction and/or consolidation therapy before the first HSCT were considered. Among them the most frequent were previous severe infection (59%), previous HSCT (35%), lung injury (Table 1 ). In addition, patients transplanted from MUD (n ¼ 27) received rabbit antithymocyte globulin (Thymoglobuline, Genzyme (Cambridge, MA, USA), n ¼ 9 or ATG-Fresenius (Fresenius, Gra¨felfing, Germany), n ¼ 10) or alemtuzumab (MabCampath, Bayer-Schering (Berlin, Germany), n ¼ 8) for in vivo T-cell depletion. Detailed information concerning the conditioning regimen, donor type, stem cell source and stem cell dose is given in Table 1 .
GvHD prophylaxis and grading
Data on GVHD prophylaxis are presented according to donor type in Table 1 . Acute and chronic GVHD was graded according to standard criteria. 20, 21 Early regimen-related toxicity grading Early RRT, until day þ 100 after HSCT, was graded according to the criteria developed by Bearman et al.
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Evaluation of post-transplant hematopoietic chimerism Chimerism was evaluated by PCR analysis with microsatellite probes or with fluorescent in situ hybridization analysis of the chromosomes X/Y composition. Complete donor chimerism (CC) was defined by the presence of X95% of donor origin blood or BM cells, whereas mixed donor chimerism by a variable percentage of donor origin blood and/or BM cells ranging from 5 to 95%. Autologous hematopoietic reconstitution (graft failure) was diagnosed when the percentage of donor origin blood and/or BM cells was o5%.
Minimal requirements for supportive care
Central venous access was inserted in all patients. Patients were cared for in a reverse isolation unit equipped with HEPA filters or laminar airflow units. In addition, a low microbial diet, trimethoprim-sulfomethoxazol and acyclovir were given. Children received i.v. substitution of 7-S Igs, and irradiated leukocyte-depleted blood products. Antiemetic prophylaxis, oral decontamination and mouth care, monitoring for bacterial, fungal and viral infections was carried out according to local standards. Anti-convulsive prophylaxis was not given during TREO treatment.
Outcome measures
Outcome was measured as follows: (1) engraftment (ANC X0.5 Â 10 9 per L on three consecutive days and/or platelet count X20 Â 10 9 per L without transfusion on seven consecutive days); (2) graft failure (primary failure-failure to reach ANC X0.5 Â 10 9 per L for at least 28 days after transplantation; secondary failure-decrease of ANC to below 0.2 Â 10 9 per L for at least three consecutive days after initial engraftment); (3) CC (rate and time from day 0 to first day of CC); (4) early RRT (up to day þ 100); (5) acute GVHD (in all children starting on day þ 1 up to day þ 100); (6) chronic GVHD (in children with sustained engraftment and surviving for more than 100 days after HSCT); (7) nonrelapse mortality (NRM); (8) relapse incidence; (9) disease-free survival (DFS).
Data collection and statistical methods
For data collection, a questionnaire approved by the EBMT was used. The cutoff for data analysis was December 31, 2005 . Collected data were analyzed using the SAS software package (V.9.1.3; SAS Institute, Cary, NC, USA) on the Windows platform. Conditional probabilities of engraftment were estimated using conditional probability functions. The distribution of complete chimerism, relapse incidence and nonrelapse mortality were estimated using cumulative incidence curves. Comparisons of cumulative incidences were made using the Gray's test, which compares subdistribution hazards between groups, computing a weighted sum of differences in nonparametric estimates of the competing risk subdistribution between groups. 23 DFS was analyzed using Kaplan-Meier methods. The log-rank tests were applied for exploratory comparison purposes. On the basis of the resulting time-to-event curves, specific rates were extracted together with their associated 90% confidence limits. All statistical tests were performed two-sided and are to be interpreted from an exploratory perspective. No adjustments for multiple testing were applied. P-values of p0.05 were considered to be statistically significant.
Results
RRT
Early RRT I1 (the degree symbol, that is, 1, refers to both RRT and GvHD grade) occurred in 17 (33%), II1 in 12 (24%) and III1 in 7 (14%) patients ( Table 2 ). The rates of early RRT I1 and II1 were similar in children conditioned with lower and higher doses of TREO, but the toxicity III1 was observed exclusively in patients who received higher doses. The major toxicity was oral mucositis (Table 2 ). In total, stomatitis occurred in 18 (35%) patients, including 5 (25%) of 21 children conditioned with the lower dose of TREO (30 g/m 2 ), and 13 (43%) of 30 children given the higher dose of TREO (36-42 g/m 2 ). Stomatitis III1 was observed exclusively in the latter group of patients (n ¼ 6; 20%). Gastrointestinal toxicity occurred in 7 (14%) recipients, including 1 (5%) out of 21 patients receiving TREO at the lower dose and in 6 (20%) out of 30 patients receiving its higher dose. Liver toxicity occurred in a total of 9 (18%) patients, in particular I1 in 7 (14%) patients and II1 in other 2 (4%). In addition, pulmonary toxicity I1 was observed in one patient (2%) and renal toxicity III1 in another (2%). Cardiac, bladder and CNS toxicity as well as early RRT IV1, that is, fatal toxicity, did not occur.
Engraftment
Myeloid engraftment was achieved in 48 (94%) patients, whereas graft failure was seen in three (6%) children. Two were conditioned with a TREO-prep-reg at a total dose of 30 g/m 2 . Both patients were alive in posttransplant CR, 37 and 6.5 months, respectively, with autologous hematological reconstitution. The third child was retransplanted on day þ 30 from the same MSD and after another round of the same conditioning (TREO þ fludarabine þ melphalan), with subsequent prompt engraftment and CC on day þ 20. The child was alive at 11.5 months from HSCT in third CR (in this data analysis only results of the first HSCT were counted).
Median neutrophil (n ¼ 51) and platelet engraftment (n ¼ 34) occurred on days 17 (range: 10-63 days) and 20 days (range: 10-65 days), respectively (Figures 1a and b) .
Hematopoietic chimerism
Chimerism was evaluated in 47 (92%) of 51 children. In three (6%), no informative marker was found (TREO dose:
) and in one (2%), chimerism was not investigated (TREO dose: 36 g/m 2 ). Overall, the cumulative incidence (CI) of CC) was 90% (90% CI (75, 100%)). In 18 patients, given the lower total TREO dose (30 g/m 2 ), the prevalence of CC on day þ 56 was 84% (n ¼ 15), whereas in 24 patients, given the higher TREO dose (36 g/m 2 ), it was 96% (n ¼ 23) (Figure 2 ). In children, given the lower dose of TREO, CC was achieved at a median of 28 days (range: 14-48 days), whereas in those given the higher dose CC occurred at a median of 25 days (range: 13-55 days), the difference was not statistically significant (P ¼ 0.327). Only three children received TREO at a total dose of 42 g/m 2 , and all three demonstrated Table 2 Early regimen related toxicity according to criteria of Bearman et al.
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Early RRT Treosulfan for allo-HSCT in childhood leukemia J Wachowiak et al prompt CC, that is, one on day þ 15 and the remaining two on day þ 26.
Acute and chronic GVHD Acute GVHD III-IV1 (the degree symbol here refers to GVHD degree) occurred in a total of 9 (18%) out of 51 children, that is in two (8%) after MSD-HSCT (n ¼ 24) and seven (26%) after MUD-HSCT (n ¼ 27). The overall rate of chronic GvHD in 46 children who demonstrated engraftment and survived for more than 100 days after HSCT was 18% with an equal incidence (9%) of limited and extensive disease. After MSD-HSCT (n ¼ 23), the total chronic GVHD rate was 13%, with 9% limited, and 4% extensive disease. For MUD-transplantations (n ¼ 23) the rates were 22, 9 and 13%, respectively. With respect to stem cell source, the incidence of acute GVHD III-IV1 was 13% after BMT, and 26% after peripheral blood stem cell transplantation, whereas in the case of chronic GVHD it was 18 and 19%, respectively.
NRM
Of the 51 patients, five (10%) died because of nonrelapse causes 59, 66, 115, 634 and 865 days after transplantation. Diagnosis, pre-HSCT factors predicting a high risk of NRM, and the main causes of NRM are shown in Table 3 . Four out of five deceased children suffered from advanced lymphoid malignancy. The CI of NRM was 4% (0-8%) at day þ 100, 8% (2-14%) at 1 year and 16% (3-28%) after 4 years from HSCT ( Figure 3) . The difference of CI at 4 years found between children transplanted in first CR (6; 0-14%) and second or higher CR (20; 4-37%) was NS (P ¼ 0.4155). The 4-year CI of NRM in 18 children undergoing second or subsequent HSCT (17; 3-31%) was almost identical to that in 33 children after the first transplant (15; 0-31%). In addition, univariate analyses showed no significant differences in NRM between TREO total dose, diagnosis, donor type, stem cell source, early RRT maximum score (that is, the highest score reached in any single organ system) and GvHD prophylaxis.
Relapse incidence
Eleven (22%) patients relapsed post transplant, the median time to relapse was 11 months (range: 2-45 months). The 4-year cumulative relapse incidence (CRI) was 24% (13-34%) with significant differences between patients transplanted from a MSD (39; 22-56%) and a MUD (8; 0-16%) (P ¼ 0.021). The 4-year relapse rates of 10 children transplanted Patients at risk 36 g/m 2 Figure 2 Cumulative incidence of complete posttransplant haematopoietic chimerism stratified by total dose of treosulfan. Data concerning cumulative incidence of complete chimerism in three children given TREO at total dose of 42 g/m 2 were not evaluated because of a small number of patients. However, all three demonstrated prompt complete chimerism, that is, one on day þ 15, and two on day þ 26.
Table 3
Non-relapse mortality-characteristic of patients and causes for myelodysplastic syndrome were 0 (0; 0-0%). It is of interest that in 18 patients conditioned with TREO-prep-reg for second or third HSCT, the 4-year CRI (17; 3-31%) was similar to that observed in 33 children prepared with this regimen for their first HSCT (28; 14-41%). In univariable analysis, no differences in CRI were found in relation to TREO total dose.
DFS
A total of 35 (67%) patients were alive in complete continuous remission after HSCT at a median observation time of 19 months (range 3-60 months). The estimated 4-year probability of DFS was 61% (45-76%) for the whole cohort of children studied (Figure 4a) , and was significantly higher in the 29 children with myeloid malignancies (AML, sAML, CML and MDS) (73; 57-89%) than in the 20 patients with lymphoid malignancies (ALL, sALL, infant ALL and NHL) (41; 18-65%) (P ¼ 0.050) (Figure 4b ). There was a statistically nonsignificant trend towards higher DFS in: (1) children receiving TREO at the total dose of 36 g/m 2 (73; 56-90%) compared with those receiving it at 30 g/m 2 (51; 27-76%) (P ¼ 0.524); (2) in patients transplanted from a MUD (77; 64-91%) compared with those transplanted from a MSD (52; 33-72%) (P ¼ 0.350) ( Figure 4a) ; (3) in children receiving peripheral blood stem cells (83; 68-97%) compared with those given BM (54; 34-83%) (P ¼ 0.234), and (4) in children transplanted in an early stage of disease (75; 57-92%) compared with those transplanted in advanced stage of disease (53; 34-73%) (P ¼ 0.181). The 4-year cumulative probability of DFS was comparable in patients conditioned with TREO-prep-reg for first (58; 38-78%) or for second or subsequent transplantation (67; 49-85%) (Figure 4c ).
Discussion
This retrospective study is the first large investigation, which reports the results of TREO-prep-reg in children and Beelen et al., 24 respectively. A significant proportion of patients received TREO also in combination with melphalan or etoposide.
Patients in this study had high-risk or advanced hematological malignancies considered as standard indications for allo-HSCT, and comorbidity factors that posed a substantial risk of life-threatening complications after standard-prep-reg. These patients were therefore, in the judgment of the participating centers, ineligible for standard myeloablative regimens. TREO-based regimens were chosen for this high-risk cohort of children and adolescents, because of the encouraging results of previous studies in adults, 6, 7 including subsequent dose finding studies. 24 In addition, a pilot study in children 19 confirmed the positive experience gained in adults. Fatal early RRT (up to day þ 100) did not occur in the studied pediatric population, despite its high-risk diseases and comorbidities. Similar to adults, 7,24,25 the major early toxicity was mucositis. It was seen in one-third of patients, and was usually mild-or-moderate, except for some III1 stomatitis in children who had received higher-dose levels of TREO (36-42 g/m 2 ). This is remarkable, as a significant proportion of these patients were given, in addition to TREO, other agents with substantial mucosal toxicity, like cyclophosphamide, VP-16 and melphalan 26 as well as 'short' MTX for GVHD prophylaxis. 22, 27 The majority of patients were at risk of veno-occlusive disease. [28] [29] [30] [31] However, similar to the experience in adult patients, 7, 24 hepatic toxicity occurred only in a minority of recipients and was usually mild, and no patient developed veno-occlusive disease. Despite pretransplant CNS injury being identified in 12% of patients and with no anticonvulsive prophylaxis given during TREOprep-reg, the CNS toxicity was not observed. This compares favorably with the liver and CNS toxicity data reported in patients conditioned with fractionated TBI-and BU-based regimens. 22, [30] [31] [32] [33] [34] In addition, no early cardiac and bladder toxicity was observed. Thus, the early organ toxicity of TREO-prep-reg observed in the studied high-risk population seems to be comparable with that of RIC. 4, [35] [36] [37] Prompt myeloid engraftment was achieved in 94% of patients, which is comparable with the engraftment rate observed after standard-prep-reg, and remains in accordance with results reported in adults. 7, 24, 25 In contrast to this, RIC consisting of BU 8 mg/kg plus fludarabine and ATG, used in children with malignant and nonmalignant disorders, resulted in an engraftment rate of only 80%. 5, 37, 38 In our study, graft failure occurred in three (6%) patients. Nevertheless, despite graft failure all three children were alive in CR, that is, the first two with autologous hematological reconstitution, and the third one after second HSCT from the same donor and after the same TREO-based regimen. In the last patient, no early RRT was observed after first HSCT, however, after the second transplantation gastrointestinal toxicity III1, hepatic and pulmonary toxicity II1 and skin toxicity I1 occurred.
The overall rate of CC on day þ 56 was 90%, and children conditioned with the higher TREO dose (36-42 g/m 2 ) showed a trend towards both a higher proportion of patients reaching CC and an earlier achievement of CC. These results are comparable with those obtained in adults 7, 24 and, together with the engraftment data, also confirm the myeloablative properties of TREO-prep-reg with a total dose X36 g/m 2 in children. In contrast, for patients with malignancies, who received RIC regimens, the probability of achieving CC was 95% only on day þ 180. 39 The overall frequency of acute GvHD III-IV1 did not differ from that observed in children with hematological malignancies conditioned for allo-HSCT with standard myeloablative [40] [41] [42] [43] or RIC 5, 36 regimens The frequency of chronic GVHD was similar 41, 43, 44 or somewhat lower 40, 45 than reported in children with leukemia or MDS undergoing allo-HSCT after standard regimens and in adults conditioned with TREO-prep-reg. 7, 24, 25 In the context of a substantially increased risk of lifethreatening transplant-related complications, the CI of NRM was unexpectedly low, and amounted to only 4% at day þ 100, 8% at 1 year and 16% after 4 years from transplantation. The observed CI of NRM was comparable with that reported recently in standard-risk children conditioned for allo-HSCT with standard-prep-reg, 41, 43, 46 and even lower than in children receiving a RIC regimen. 34 In contrast to the high incidence of NRM in patients conditioned for second HSCT with standard-prep-reg, 47, 48 in the children studied here, the 4-year CI of NRM was almost the same after the first or a second HSCT.
The 4-year CRI (24%) in the studied cohort of children with high-risk or advanced hematological malignancies was lower than anticipated, especially in children transplanted from unrelated donor (8%) and in children with MDS (0%). It is of interest that, in children undergoing second HSCT, not only NRM, but also CRI was comparable with that observed in children transplanted for the first time and lower than reported in children with hematological malignancies receiving standard-prep-reg before second HSCT. 47, 48 The estimated 4-year probability of DFS was 61% for the whole studied cohort of children, who were otherwise deemed to be ineligible for standard-prep-reg. The probability of DFS was significantly better in children with myeloid malignancies (73%), than in those with lymphoid malignancies (41%). These findings seem to confirm the significant anti-leukemic efficacy of TREO-prep-reg, which appears to be comparable with that of standard-prep-reg in childhood hematological malignancies. 43, 46, 49, 50 The significant anti-leukemic effect of TREO-based conditioning regimens along with their low toxicity, makes them also an attractive alternative to RIC regimens, especially for patients with high-risk hematological malignancies, in whom relapse remains the most common obstacle to a successful outcome of RIC. 4, [35] [36] [37] However, as a prodrug nonenzymatically activated to alkylating mono-and diepoxides, TREO demonstrates gonadotoxicity and mutagenicity, and thus monitoring and evaluation of its long-term effects, including secondary MDS in children demonstrating mixed chimerism, will be of special importance in children conditioned for HSCT with high-dose TREO.
In conclusion, this retrospective study has shown that children with high-risk or advanced hematological malignancies, and at substantial risk of life-threatening complications after conventional allo-HSCT can be transplanted effectively and safely using TREO-based regimens. The myeloablative, immunosuppressive and anti-leukemic efficacy of these regimens appears to be comparable with that reported for BU-based regimens, with toxicity comparable with that of RIC regimens. Thus, the TREObased regimens seem to combain advantageous features of conventional and RIC regimens. Particularly favorable results have been achieved in children with myeloid malignancies and in children undergoing a subsequent HSCT. Hence, there is a strong case for licencing this drug for children and therefore a need for prospective clinical trials including all prerequisities for Good Clinical Practiceconformed studies in the interest of developing better treatment modalities for children and adolescents.
Conflict of interest
Dr Wachowiak and Dr Sykora have received reimbursement for attending conferences from Medac. Dr Cornish, Dr Chybicka, Dr Kowalczyk, Dr Gorczynska, Dr Choma, Dr Grund and Dr Peters declare no potential conflict of interest.
